Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Inhibikase Therapeutics (IKT) Other financing activities (2024)

Inhibikase Therapeutics (IKT) has 1 years of Other financing activities data on record, last reported at -$30608.0 in Q1 2024.

On a quarterly basis, Other financing activities changed N/A to -$30608.0 in Q1 2024 year-over-year; TTM through Mar 2025 was -$30608.0, a N/A change, with the full-year FY2023 number at -$138556.0, changed N/A from a year prior.
Other financing activities reached -$30608.0 in Q1 2024 per IKT's latest filing.
Over the last five years, Other financing activities for IKT hit a ceiling of -$30608.0 in Q1 2024 and a floor of -$30608.0 in Q1 2024.